Indoco Remedies Ltd
NSE: INDOCO BSE: 532612
₹192.20
(1.80%)
Mon, 23 Mar 2026, 05:42 pm
Market Cap17.66B
PE Ratio0
Dividend0.10
Health Technology
Pharmaceuticals: Major
24.5KCompany History
1945
- Mr. Govind Ramnath Kare started a firm which he named Indo Continental Trading Company
1947
- A new Company was founded with the intent to manufacture and sell pharmaceutical formulations
- The manufacturing operations were started in a small house in Thane near Mumbai
1963
- Mr. Suresh Kare, son of Mr. G.R. Kare came to Mumbai and took over as Managing Director of the then sick unit
1969
- The Company has a turnover of Rs. 1 Million and a total employee strength of around 50
2005
- Indoco Remedies enters into an Agency Agreement with SRU
2006
- Indoco Remedies mulls to enter US mkt
- Indoco Remedies secures US FDA approvals
- Board has proposed a dividend of 62.5%
2007
- Mr. J. B. Salian has been appointed the Secretary of the Company
- Board has proposed a dividend of 65% .
2008
- Board has recommended a dividend of Rs 5.00 per share
- IDMA Quality Excellence Awards 2008 - The Sterile Facility at Goa Plant II received the Gold Award and the Solid Dosage Forms and Externals Facility at Goa Plant I received the Silver Award
- First shipment of Diclofenac Ophthalmic solution shipped to USA against an approved ANDA
2009
- Board has decided to declare a final dividend of Rs 2.00 per equity share
- UK-MHRA approval for the Solid Oral Dosage forms at Baddi Plant
- Successfully faced Slovenia audit for the Sterile Facility at Goa Plant II for the Injections Area
2010
- The Company has signed an agreement with Aspen Pharmacare, South Africa for supply of ophthalmic products
- Board has recommended a payment of divided of Rs. 7.00 per equity share
- Indoco Remedies teams up with ASPEN, South Africa by licensing out intellectual property (dossiers) for marketing its products in emerging markets covering 30 countries, including SA, Brazil, Mexico, Venezuela, Russia & Australia
2011
- Board has recommended a dividend of Rs. 8/- per equity share
- Indoco received the Silver Quality Excellence Award for Sterile Manufacturing Facility in Goa and Solid Dosages Facility in Baddi (HimachalPradesh) at IDMA's Golden Jubilee celebrations
2012
- Indoco Remed - Enters into a strategic business alliance with DSM Pharmaceutical Products (DPP) NV
- Mr. Sunil Joshi has been appointed as Company Secretary & Compliance Officer of the Company
- Indoco announced the signing of an agreement with DSM, a € 9 billion Company, for commercial cooperation for Active Pharmaceutical Ingredients (APIs)
- Company has splits its Face value of Shares from Rs 10 to Rs 2
- Indoco Remedies has given the Bonus in the Ratio of 1:2
2013
- Indoco Remedies Ltd. has received the approval from United States Food & Drug Administration (USFDA) to manufacture and market GLIMEPIRIDE 1mg, 2mg & 4mg tablets
- Indoco Remedia Ltd. has recommended payment of dividend of Rs.1.10 per equity share on the face value of Rs. 2/- each i.e. 55% for financial year 2012-13
2014
- US-FDA approves Sterile (Plant II) and Solid Dosages (Plant III) facilities in Goa
- IDMA Best Patent Award for Tazarotene & Adapalene
- Indoco Remedies Ltd. has Certificate of Good Manufacturing Practice (GMP) Compliance of a Manufacturer
2015
- Indoco wins IDMA Patent Appreciation Award for Betaxolol
- Indoco acquires Piramal's Clinical Research Division
2016
- Indoco acquires Manufacturing plant at Baddi
- Indoco Honoured with the IDMA Best Patent Award for Three International Patents
- Indoco honoured with the 'Best Patent Award' by PHARMEXCIL in the Bulk Drugs / API category
2017
- Indoco receives the Express Pharma Export Excellence Award 2017
- Indoco receives UKMHRA approval for solid dosages Plant I in Goa
- Indoco receives the IDMA Best Patent Award for four API Process Patents
- Indoco receives patent grant for Linezolid & Brinzolamide (FDFs) from United States Patent and Trademark Office (USPTO)
2018
- Indoco commissions For New API manufacturing facility at Patalganga
- Indoco's Goa Plant II & III clears USFDA inspection
- Indoco's API manufacturing facilities at Patalganga and Rabale successfully clear USFDA inspection
- Indoco's API Patalganga site receives Renewed Accreditation Certificate from The Pharmaceuticals and Medical Devices Agency (PMDA), Japan
- Indoco receives the IDMA Best Indian Patent Award for five API Process Patents
- Indoco's Goa plant III receives EU GMP certification
2019
- Indoco successfully completes UK-MHRA inspection at Goa Plant II
- Indoco gets European Patent Grant for unique process of Brinzolamide Eye Drops
- Indoco wins the IDMA Formulations Patent Award 2017-18 for 2 International and 1 Indian patent
- Indoco's new solid dosages facility at Baddi receives UK-MHRA approval
- Indoco's Sterile Manufacturing Facility (Plant II) Clears USFDA Inspection
2020
- Indoco wins major tenders in Germany for Allopurinol Tablets
- Indoco receives USFDA approval for Apixaban Tablets 2.5 mg & 5 mg
- Indoco awarded with the IDMA Formulations Best Patent Award 2018-19 for 2 formulation patents Diclofenac & Quetiapine
- Indoco receives USFDA approval for Succinylcholine Chloride Injection USP
- Indoco receives USFDA approval for Olanzapine Tablets
2021
- Indoco announces the launch of Brinzolamide Ophthalmic Suspension 1% in the US market by Teva Pharmaceuticals
2022
- Indoco Remedies to acquire stake in Kanakal Wind Energy.
- Indoco Remedies receives USFDA approval for Lacosamide Injection USP.
- Indoco Remedies receives USFDA approval for Lacosamide Tablets.
2023
- Indoco Remedies receives tentative ANDA approval from USFDA for Canagliflozin Tablets.
- Indoco acquires 85 % equity stake in US based FPP Holding Company, LLC.
- Indoco receives EIR for its manufacturing facility in Goa (Plant I).
2024
- Indoco enters into a strategic distribution partnership with Clarity Pharma, UK.
- Indoco Remedies receives final ANDA approval from USFDA for Varenicline Tablets, 0.5 mg and 1 mg
- Indoco Remedies receives final ANDA approval from USFDA for Pregabalin capsules.
- Indoco Remedies receives tentative ANDA approval from USFDA for Canagliflozin and Metformin Hydrochloride Tablets.
- USFDA successfully completes inspection at Indoco's API Kilo Lab manufacturing facility and IAS division without any observations.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800